Lisinopril diydrate
Modify Date: 2025-08-20 15:11:49
Lisinopril diydrate structure
|
Common Name | Lisinopril diydrate | ||
|---|---|---|---|---|
| CAS Number | 83915-83-7 | Molecular Weight | 441.52 | |
| Density | 1.251 g/cm3 | Boiling Point | 666.4ºC at 760 mmHg | |
| Molecular Formula | C21H35N3O7 | Melting Point | 160ºC (Decomposes) | |
| MSDS | USA | Flash Point | 356.9ºC | |
Use of Lisinopril diydrateLisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.Target: ACELisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy [1, 2]. |
| Name | lisinopril dihydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Lisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.Target: ACELisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy [1, 2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.251 g/cm3 |
|---|---|
| Boiling Point | 666.4ºC at 760 mmHg |
| Melting Point | 160ºC (Decomposes) |
| Molecular Formula | C21H35N3O7 |
| Molecular Weight | 441.52 |
| Flash Point | 356.9ºC |
| PSA | 132.96000 |
| LogP | 2.26430 |
| Index of Refraction | -45 ° (C=1, 0.25mol/L Zinc Acetate Buffer) |
| Storage condition | 2-8°C |
| Stability | Hygroscopic |
| Water Solubility | H2O: ≥10 mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi,Xn |
| Risk Phrases | R20/21/22 |
| Safety Phrases | S22-S24/25 |
| RIDADR | TW3589990 |
| WGK Germany | 3 |
| RTECS | TW3589990 |
| HS Code | 2933990090 |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Isolation and characterization of a novel angiotensin-converting enzyme-inhibitory tripeptide from enzymatic hydrolysis of soft-shelled turtle (Pelodiscus sinensis) egg white: in vitro, in vivo, and in silico study.
J. Agric. Food Chem. 62(50) , 12178-85, (2014) In this study, a novel angiotensin-converting enzyme (ACE)-inhibitory tripeptide (IVR) was isolated and identified from unfertilized soft-shelled turtle egg white (SSTEW). The IC50 value of IVR was me... |
|
|
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
JAMA 310(9) , 918-29, (2013) Most patients with cardiovascular disease (CVD) do not take recommended medications long-term. The use of fixed-dose combinations (FDCs) improves adherence in several clinical areas. Previous trials o... |
|
|
Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension.
Clin. Sci. 127(1) , 57-63, (2014) The somatic isozyme of ACE (angiotensin I-converting enzyme) comprises two distinct zinc-dependent catalytic domains with different substrate specificities for angiotensin I (cleaved selectively by th... |
| L-Proline, N-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2) |
| (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate |
| N-[(1S)-1-Carboxy-3-phenylpropyl]-L-lysyl-L-proline dihydrate |
| MFCD08064198 |
| Lisinopril Dihydrate |
| EINECS 278-488-1 |
| Lisinopril diydrate |
| Lisinopril (dihydrate) |